Pyroptosis inducer-1
Pyroptosis inducer-1 is a pyroptosis inducer. Pyroptosis inducer-1 promotes STING phosphorylation, NF-κB activation, caspase-1-dependent pyroptosis, GSDMD cleavage, mitochondrial membrane potential disruption, ROS production, S phase cell cycle arrest, ER stress, calcium release, and immunogenic cell death accompanied by CRT exposure, HMGB1 release, and ATP secretion. Pyroptosis inducer-1 enters cancer cells via endocytosis and accumulates in mitochondria and endoplasmic reticulum. Pyroptosis inducer-1 increases dendritic cells and CD8+ T cells while decreasing regulatory T cells. Pyroptosis inducer-1 can be used for breast cancer research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3081319-75-4
- Formule: C54H46ClF8N8O2PRu
- Masse moléculaire:1158.48
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
Description
Pyroptosis inducer-1 is a pyroptosis inducer. Pyroptosis inducer-1 promotes STING phosphorylation, NF-κB activation, caspase-1-dependent pyroptosis, GSDMD cleavage, mitochondrial membrane potential disruption, ROS production, S phase cell cycle arrest, ER stress, calcium release, and immunogenic cell death accompanied by CRT exposure, HMGB1 release, and ATP secretion. Pyroptosis inducer-1 enters cancer cells via endocytosis and accumulates in mitochondria and endoplasmic reticulum. Pyroptosis inducer-1 increases dendritic cells and CD8+ T cells while decreasing regulatory T cells. Pyroptosis inducer-1 can be used for breast cancer research[1].
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
1.43 μM
|
Antiproliferative activity against human breast cancer MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs.
Antiproliferative activity against human breast cancer MCF-7 cells assessed as reduction in cell viability incubated for 48 hrs.
|
42570373 |
| 143B | IC50 |
1.36 μM
|
Antiproliferative activity against human osteosarcoma 143B cells assessed as reduction in cell viability incubated for 48 hrs.
Antiproliferative activity against human osteosarcoma 143B cells assessed as reduction in cell viability incubated for 48 hrs.
|
42570373 |
| Caco-2 | IC50 |
3.40 μM
|
Antiproliferative activity against human colorectal cancer Caco-2 cells assessed as reduction in cell viability incubated for 48 hrs.
Antiproliferative activity against human colorectal cancer Caco-2 cells assessed as reduction in cell viability incubated for 48 hrs.
|
42570373 |
| HeLa | IC50 |
1.27 μM
|
Antiproliferative activity against human cervical cancer HeLa cells assessed as reduction in cell viability incubated for 48 hrs.
Antiproliferative activity against human cervical cancer HeLa cells assessed as reduction in cell viability incubated for 48 hrs.
|
42570373 |
| HepG2 | IC50 |
1.75 μM
|
Antiproliferative activity against human hepatocellular carcinoma HepG2 cells assessed as reduction in cell viability incubated for 48 hrs.
Antiproliferative activity against human hepatocellular carcinoma HepG2 cells assessed as reduction in cell viability incubated for 48 hrs.
|
42570373 |
| MCF-10A | IC50 |
4.72 μM
|
Antiproliferative activity against non-tumorigenic human mammary epithelial MCF-10A cells assessed as reduction in cell viability incubated for 48 hrs.
Antiproliferative activity against non-tumorigenic human mammary epithelial MCF-10A cells assessed as reduction in cell viability incubated for 48 hrs.
|
42570373 |
In Vitro
Anti-cancerMitochondrial FunctionOxidative StressCell Cycle RegulationPyroptosisEndoplasmic Reticulum Stress
Anti-cancer
Pyroptosis inducer-1 (Ru3) (48 h) exhibits potent broad-spectrum antiproliferative activity against human cancer cell lines, including MCF-7, with IC50 values ranging from 1.27 to 3.40 μM[1].
Pyroptosis inducer-1 (2 μM; 30 min-4 h) rapidly enters MCF-7 cells via an endocytosis-associated pathway and preferentially accumulates in the mitochondria and endoplasmic reticulum[1].
Pyroptosis inducer-1 (2 μM; 30 min-4 h) rapidly enters MCF-7 cells via an endocytosis-associated pathway and preferentially accumulates in the mitochondria and endoplasmic reticulum[1].
Mitochondrial Function
Anti-cancer
Pyroptosis inducer-1 (2-6 μM; 8 h) induces significant mitochondrial membrane depolarization and dysfunction in MCF-7 cells[1].
Pyroptosis inducer-1 (2-6 μM) effectively induces the release of multiple DAMPs (CRT exposure, HMGB1 release, ATP secretion) in MCF-7 cells, thereby triggering ICD-related responses[1].
Pyroptosis inducer-1 (2-6 μM) effectively activates the cGAS-STING signaling pathway in MCF-7 cells, potentially exerting antitumor immunomodulatory effects[1].
Pyroptosis inducer-1 (2-6 μM) effectively induces the release of multiple DAMPs (CRT exposure, HMGB1 release, ATP secretion) in MCF-7 cells, thereby triggering ICD-related responses[1].
Pyroptosis inducer-1 (2-6 μM) effectively activates the cGAS-STING signaling pathway in MCF-7 cells, potentially exerting antitumor immunomodulatory effects[1].
Oxidative Stress
Anti-cancer
Pyroptosis inducer-1 (2-6 μM) induces pronounced intracellular oxidative stress through massive ROS accumulation in MCF-7 cells[1].
Anti-cancer
Cell Cycle Regulation
Pyroptosis inducer-1 (2-6 μM; 24 h) disrupts normal cell cycle progression and inhibits the proliferative capacity of MCF-7 cells through induction of S-phase arrest[1].
Anti-cancer
Pyroptosis
Pyroptosis inducer-1 (2-6 μM; 8-24 h) triggers caspase-1-dependent pyroptosis in MCF-7 cells, characterized by morphological changes and release of pro-inflammatory cytokines[1].
Endoplasmic Reticulum Stress
Anti-cancer
Pyroptosis inducer-1 (2-6 μM; 6 h) effectively induces ER stress in MCF-7 cells, characterized by calcium release and activation of the eIF2α-ATF4-Chop signaling axis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Immunofluorescence[1]
-
Cell Line:MCF-7
-
Concentration:2 μM
-
Incubation Time:30 min; 4 h; 1 h
-
Result:Intracellular red fluorescence was detectable after 30 min, with intense distribution in the cytoplasm after 4 h.
Colocalized significantly with mitochondrial (PCC = 0.68) and ER (PCC = 0.73) probes, but showed limited overlap with lysosomal probe (PCC = 0.49).
Cell Cycle Analysis[1]
-
Cell Line:MCF-7
-
Concentration:2 μM; 4 μM; 6 μM
-
Incubation Time:24 h
-
Result:Markedly induced S-phase arrest.
The proportion of cells in the S phase increased from 25.8% in the control group to 41.1% following treatment with 6 μM Ru3.
The percentage of cells in the G2/M phase decreased from 26.3% to 16.2%.
ELISA Assay[1]
-
Cell Line:MCF-7
-
Concentration:2 μM; 4 μM; 6 μM
-
Incubation Time:8 h; 24 h
-
Result:Treated cells exhibited typical pyroptotic morphological features including cellular swelling, membrane disruption, and bubble-like protrusions.
ELISA showed significantly elevated extracellular levels of IL-6, TNF-α, and IFN-β.
NSA pretreatment attenuated Ru3-induced cytotoxicity.
Western blot demonstrated concentration-dependent upregulation of Cleaved-Caspase-1 and increased GSDMD-N expression.
Immunofluorescence[1]
-
Cell Line:MCF-7
-
Concentration:2 μM; 4 μM; 6 μM
-
Incubation Time:6 h
-
Result:Increased the fluorescence intensity of Fluo-3 (HY-126821) in a concentration-dependent manner.
In Vivo
Anti-cancerAdaptive ImmunityImmune Tolerance & Immunosuppression
Anti-cancer
Adaptive Immunity
Immune Tolerance & Immunosuppression
Pyroptosis inducer-1 (Ru3) (6 μM; s.c.; single dose) vaccination induces potent antitumor immunity in vivo, achieving a tumor growth inhibition rate of 86.69% on day 30 and significantly enhancing infiltration of DCs and CD8+ T cells while reducing immunosuppressive Tregs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female)[1]
-
Dosage:6 μM
-
Administration:s.c.; single dose
-
Result:Inhibited tumor growth with a tumor growth inhibition rate of 80.21% on day 16 and 86.69% on day 30.
Increased the proportion of CD11c+ dendritic cells in the spleen by approximately 2.5-fold.
Increased the number of CD4+ T cells in the spleen and tumors by approximately 5.9-fold and 3.6-fold, respectively.
Increased the proportion of CD8+ T cells in the spleen and tumors by approximately 5.9-fold and 3.2-fold, respectively.
Reduced the proportion of regulatory T cells (Tregs) in the spleen and tumors, which were approximately 3.4-fold and 6.2-fold higher in control mice, respectively.
Related Protocols :
- Western Blot
- Mitochondrial membrane-potential fluorescent assay
- Mammalian live/dead viability and cytotoxicity staining
- ROS/oxidative-stress fluorescent staining
- BrdU Incorporation Assay
- Protocol for Cell Cycle
- Research Protocol for Inflammation-related Diseases
- Breast Cancer Modeling
- Kinase activity and phosphorylation assays
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Flow cytometric DNA-content cell-cycle staining
- Cell Cytotoxicity Assay
- Fluorescent plasma-membrane potential dye assay
- Mitochondrial membrane-potential and mitochondrial mass staining
- Apoptosis Solutions
- Calcium Spark Assay
- Protocol for Kinase activity and phosphorylation assays
- Monocyte-derived dendritic cell differentiation
- Pyroptosis Solutions
Chemical Information
-
CAS No. 3081319-75-4
-
Masse moléculaire 1158.48
-
Formule C54H46ClF8N8O2PRu
-
SMILES
O=C(COCCN1CCN(C(C2=CC=C(C=C2)Cl)C3=CC=CC=C3)CC1)NC4=CC5=CC=C[N]6=C5C7=[N]([Ru+2]689([N]%10=C(C%11=[N]9C=CC=C%11)C=CC=C%10)[C-]%12=C(C%13=[N]8C=CC=C%13)C(F)=CC(F)=C%12)C=CC=C74.[F-][P+5]([F-])([F-])([F-])([F-])[F-]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Select Batch:
Pureté:
99.98%
Assay:
99.98%
ee.:
99.98%
Références
Calculators
Calculateur de molarité
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
=
×
×
Calculateur de dilution
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pyroptosis inducer-1 Related Classifications
HY-189386 Related Classifications
Powered by Bioz
Keywords
- Pyroptosis inducer-1
- 3081319-75-4
- Pyroptosis inducer1
- Pyroptosis inducer 1
- Pyroptosis
- STING
- NF-κB
- Caspase
- Reactive Oxygen Species (ROS)
- Stimulator of Interferon Genes
- TMEM173
- MITA
- ERIS
- MPYS
- Nuclear factor-κB
- Nuclear factor-kappaB
- GSDMD cleavage
- mitochondrial membrane potential disruption
- S-phase cell cycle arrest
- cGAS-STING pathway
- STING phosphorylation
- pyroptosis
- ER stress
- caspase-1-dependent pyroptosis
- ROS generation
- NF-κB activation
- Inhibitor
- inhibitor
- inhibit